# A Dose-escalation Study of Lipotecan® Plus Radiotherapy in Locally Advanced Hepatocellular Carcinoma

> **NCT01425996** · PHASE1,PHASE2 · TERMINATED · sponsor: **Taiwan Liposome Company** · enrollment: 3 (actual)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **DRUG:** Lipotecan® (TLC388)

## Key facts

- **NCT ID:** NCT01425996
- **Lead sponsor:** Taiwan Liposome Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-10-27
- **Primary completion:** 2014-10-03
- **Final completion:** 2014-10-03
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2018-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01425996

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01425996, "A Dose-escalation Study of Lipotecan® Plus Radiotherapy in Locally Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01425996. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*